VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind placebo-controlled, parallel group study to
evaluate the efficacy and safety of VTX958 in participants with moderately to severely active
CD.